Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 523

1.

ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.

Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, Roberts C, Desai M, Peto J; ARTISTIC Trial Study Group.

Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv. doi: 10.3310/hta13510.

PMID:
19891902
[PubMed - indexed for MEDLINE]
Free Article
2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

PMID:
24762804
[PubMed - in process]
Free Article
3.

MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial.

Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, Gray A, Sadique Z, Moss S; MAVARIC Trial Study Group.

Health Technol Assess. 2011 Jan;15(3):iii-iv, ix-xi, 1-170. doi: 10.3310/hta15030.

PMID:
21266159
[PubMed - indexed for MEDLINE]
Free Article
4.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
[PubMed - indexed for MEDLINE]
5.

[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].

Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Review. Italian.

PMID:
23139163
[PubMed - indexed for MEDLINE]
6.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

PMID:
22828243
[PubMed - indexed for MEDLINE]
7.

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group.

Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18.

PMID:
20089449
[PubMed - indexed for MEDLINE]
8.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
[PubMed - indexed for MEDLINE]
Free Article
9.

Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.

Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A.

BMJ. 2012 Nov 29;345:e7789. doi: 10.1136/bmj.e7789.

PMID:
23197596
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.

Kim JJ, Wright TC, Goldie SJ.

JAMA. 2002 May 8;287(18):2382-90.

PMID:
11988059
[PubMed - indexed for MEDLINE]
11.

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL, Coldman AJ.

BMC Cancer. 2010 Mar 24;10:111. doi: 10.1186/1471-2407-10-111.

PMID:
20334685
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial.

Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J; ARTISTIC Trial Study Group.

Br J Cancer. 2006 Jul 3;95(1):56-61. Epub 2006 Jun 13.

PMID:
16773068
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ.

Lancet Oncol. 2012 Jan;13(1):78-88. doi: 10.1016/S1470-2045(11)70296-0. Epub 2011 Dec 14.

PMID:
22177579
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

Goldie SJ, Kim JJ, Wright TC.

Obstet Gynecol. 2004 Apr;103(4):619-31.

PMID:
15051550
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK.

Gynecol Oncol. 2010 Nov;119(2):237-42. doi: 10.1016/j.ygyno.2010.07.004. Epub 2010 Aug 14.

PMID:
20713299
[PubMed - indexed for MEDLINE]
16.

Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.

Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P.

Obstet Gynecol. 2007 Jun;109(6):1325-31.

PMID:
17540804
[PubMed - indexed for MEDLINE]
17.

Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.

Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M.

Lancet. 2011 Nov 26;378(9806):1868-73. doi: 10.1016/S0140-6736(11)61522-5. Epub 2011 Nov 1.

PMID:
22051739
[PubMed - indexed for MEDLINE]
18.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

PMID:
16030305
[PubMed - indexed for MEDLINE]
Free Article
19.

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.

Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ.

Br J Cancer. 2012 Dec 4;107(12):1917-24. doi: 10.1038/bjc.2012.489. Epub 2012 Nov 20.

PMID:
23169286
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk